The 93rd Electron mission went off without a hitch on Friday, delivering a synthetic aperture radar satellite for Japanese operator iQPS into a 575-kilometer orbit from Launch Complex 1. It marked the 14th Electron flight of the year, the ninth for iQPS, and extended a flawless success rate with the customer. Nine more iQPS missions are already booked through 2030, with the contract recently expanded by three additional flights.
And the stock barely blinked — or rather, it blinked in the wrong direction. Shares had already shed more than 4 percent in the days surrounding the launch, closing Thursday at €62.80, down 3.2 percent on the day and 9.4 percent for the week. The sell-off had little to do with rocket mechanics and everything to do with the deal that now defines Rocket Lab’s trajectory: the proposed $8 billion acquisition of Iridium.
The market has moved past launch-by-launch updates
There was a time when a clean Electron mission would galvanize the stock. That era appears over. With the company’s operational cadence now firmly established — 14 launches this year, a record $234.1 million in second-quarter revenue that edged past the $230.94 million consensus, and third-quarter guidance of $250–265 million — investors are no longer rewarding execution. They’re pricing transformation.
That transformation carries a hefty price tag. Iridium contributes roughly $870 million in revenue and $114 million in net income, while Rocket Lab itself posted around $600 million in revenue for 2025 alongside a net loss. To bridge the gap, the company has taken on a $3.6 billion bridge loan — a level of strategic leverage that signals just how far management is willing to go to pivot from launch provider to vertically integrated space operator with direct consumer revenue streams.
The prize, if integration succeeds: access to MSS spectrum, recurring revenue from 2.55 million Iridium subscribers, and a partner network spanning more than 500 companies. CEO Peter Beck has said the L-band spectrum would enable services that don’t yet exist, rather than positioning Rocket Lab as a direct Starlink competitor — an ambition that remains a strategic declaration rather than a proven business model.
Volatility is the price of admission
The market’s ambivalence is reflected in the numbers. The stock trades with an annualized 30-day volatility of 79 percent, among the highest in the sector. It sits roughly 13 percent below its 50-day moving average and about 53 percent off the May 52-week high of €133.80, though it remains 93 percent above the year’s low of €32.60. Over twelve months, the shares are still up 75 percent.
Should investors sell immediately? Or is it worth buying Rocket Lab?
That wide band captures the tug-of-war between operational strength and valuation anxiety. Some market observers peg Rocket Lab at roughly 91 times revenue — a multiple that contributed to a sector-wide pullback in early summer, amplified by the New Glenn explosion at Blue Origin and speculation around SpaceX’s valuation. The recent release of 319 million SpaceX shares added another layer of pressure to the broader new-space complex, with Rocket Lab explicitly flagged as a bellwether for sentiment in the group.
The bull case rests on a growing backlog
Supporting the optimists is a backlog that reached $2.36 billion, up 137 percent year over year. Government contracts continue to accumulate: the company was named to the US Space Force’s NITE-STAR program with a contract value of $981 million, and separately secured $266 million for HASTE launches from Alaska. The $816 million Space Development Agency deal and the recently completed acquisition of Motiv Space Systems round out a pipeline that keeps the operational story credible.
A successful Iridium integration would create an entity with its own launch vehicle, its own satellite constellations, and an established subscriber base — a stack that decouples Rocket Lab from the commoditized launch-as-a-service model.
The bear case centers on timing and leverage
The counterargument is equally clear. The Neutron rocket, central to future larger payloads, has slipped to the fourth quarter of 2026 — a schedule risk that could dampen the growth narrative. The Iridium transaction remains in financing and regulatory review, with the bridge loan requiring refinancing. Any delay would compound an already aggressive debt posture.
For now, the operational foundation holds: launch cadence is steady, the iQPS relationship is deepening, and the Space Force contracts are moving forward. The recent dip below the 50-day average looks more like a valuation correction than a deterioration of fundamentals. But the next real catalysts — progress on the Iridium deal and the Neutron debut — will determine whether this stock trades on its present or its promise. Further Electron missions, however flawless, are unlikely to move the needle either way.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from August 21 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 21.
Rocket Lab: Buy or sell? Read more here...
